Stay updated on Gene Transfer for SMA Type 1 Clinical Trial
Sign up to get notified when there's something new on the Gene Transfer for SMA Type 1 Clinical Trial page.

Latest updates to the Gene Transfer for SMA Type 1 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new 2021 Drug Saf publication citation is added, and the Erratum citation from 2022 is removed. The page revision is updated to v3.5.4.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now includes an additional referenced publication related to onasemnogene abeparvovec in spinal muscular atrophy type 1. The page revision/version label has also been updated from the previous revision number.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded a new bibliographic entry for the Day et al. paper on Onasemnogene Abeparvovec Therapy, including an Erratum, with revision noted as v3.5.2. Removed the older version of the same reference (revision v3.5.0).SummaryDifference0.1%

- Check70 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded Nationwide Children’s Hospital; removed The Research Institute at Nationwide Children’s Hospital.SummaryDifference0.1%

Stay in the know with updates to Gene Transfer for SMA Type 1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gene Transfer for SMA Type 1 Clinical Trial page.